MNGIE Natural History Study

A Retrospective Natural History Study of Subjects Affected by Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

The MNGIE Retrospective Natural History Study is a collaborative study between the University of Cambridge and the University of Bologna. The aim of this study is to better understand the natural history and progression of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).

New treatment strategies for MNGIE, including gene therapies, enzyme replacement therapy, and other advanced treatments, are currently being developed and may soon be tested in clinical trials. A comprehensive and up-to-date natural history study of MNGIE is therefore very important to help inform the design of these clinical trials and to identify appropriate clinical and biochemical outcome measure.

This international natural history study aims to include as many patients with MNGIE (living or deceased) as possible, worldwide. This study will collect anonymised clinical information through a secure online REDcap database hosted at the University of Cambridge. Focus will be on describing clinical progression, and identifying biochemical, molecular, histological, and histochemical parameters that can help in early diagnosis, improve prognosis, and better understand therapeutic outcomes.

The study is funded by Pierrepont Therapeutics Inc, and has received ethical approval from the University of Cambridge Human Biology Research Ethics Committee. Clinicians caring for MNGIE patients, are invited to contact the study team, and will then receive a direct link to the survey. Patients are asked to share information about the study with their treating clinician, if they would like their (anonymous) clinical information to be included in the study.

More information and contact details are available online (https://mitocamb.medschl.cam.ac.uk/our-research/research-studies/understanding-studies/a-retrospective-natural-history-study-of-subjects-affected-by-mitochondrial-neurogastrointestinal-encephalomyopathy-mngie/).

Study Overview

• Status: Recruiting
• Conditions: MNGIE; Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Detailed Description

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE, ORPHA#298; OMIM#603041) is an autosomal recessive disease caused by loss-of-function mutations in TYMP, the gene encoding the enzyme thymidine phosphorylase (TP).

Epidemiology and disease course:

MNGIE is an ultra-rare disease with limited available epidemiological studies. Most of the knowledge about disease course of MNGIE derives from single centre experiences, case reports, and two retrospective observational cohort studies published so far. MNGIE is a chronic debilitating and ultimately fatal condition, with average age of diagnosis around 18 years. Depending on the studied cohort, the majority of patients are thought not to survive beyond 40 years.

The earliest and most debilitating signs of MNGIE are gastrointestinal (GI), with a wide range of symptoms reported (including abdominal pain and cramps, nausea or vomiting, diarrhoea or constipation, pseudo-obstruction and gastroparesis, dysphagia, malabsorption and cachexia). GI symptoms occur in almost all reported patients. Other typical symptoms are primary mitochondrial myopathy with weakness of the eye muscles (chronic progressive external ophthalmoplegia and ptosis) in almost all patients, and peripheral neuropathy also found in most patients. All patients have leukoencephalopathy on brain magnetic resonance imaging (MRI), but this is thought to remain asymptomatic.

A wide range of other clinical features have been reported in retrospective cohort studies, and through many additional case reports in the literature. However, a comprehensive review of clinical and laboratory data from all reported and unpublished patients is lacking, and many aspects of the disease remain poorly understood.

Study rationale:

Innovative treatment strategies are emerging for MNGIE, including with ATMPs that are currently undergoing regulatory approval for clinical studies. An up-to-date and comprehensive retrospective natural history study is important to better characterize the typical presentation, clinical phenotype and progression of MNGIE, and to inform patient management, clinical trial design and the choice of clinical and biochemical outcome measures in the future.

For this, natural history data based on standardised clinical data collection are required, with quantitative measures, and taking into account the various treatment modalities currently on offer. This study is set up to include as many as possible of the published and unpublished cases of MNGIE patients worldwide, providing a deep characterization of the clinical features of this syndrome, identifying biochemical, molecular genetics, and histological/ histochemical parameters for early diagnosis and prognosis, and better understanding of therapeutic outcomes. This will also provide further knowledge about the epidemiology and establish a large database about clinicians currently involved in care for MNGIE patients, who can be approached to offer their patients the possibility to be contacted about novel and emerging interventional trials.

Research objective:

The overall aim of this study is to conduct a retrospective natural history study of patients who received a molecular or biochemical diagnosis of MNGIE worldwide, in order to comprehensively describe the presentation and clinical progression of MNGIE, define genetic and clinical subgroups, and make an inventory of treatment strategies currently being offered and their impact on disease progression. The study will capture standardised, anonymous clinical data from clinicians involved in care for MNGIE patients.

Specific Study Objectives:

• Characterize the clinical phenotype, symptom onset and progression of patients affected by genetically or biochemically confirmed MNGIE.
• Evaluate clinical symptoms and biomarkers most predictive of disease progression, and amenable to develop as outcome measures for future clinical trials.
• Identify common or different patterns of disease manifestation and progression in MNGIE patients to establish genotype-phenotype correlation-based subgroups.
• Inform treatment in MNGIE based on the outcomes from the therapeutic options available so far.
• Identify unmet needs to prioritize future research.
• Establish a database of clinicians currently involved in care for MNGIE patients

Study outcomes:

This study will lead to a detailed understanding of the symptoms and clinical manifestations present in patients with MNGIE, their onset and progression, and their response to available treatments. Study results will be detailed in a clinical study report, published as an open-access paper in a peer-reviewed journal, and presented at scientific and disease-focused conferences.

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Jelle van den Ameele; Phone Number: +44 (0)1223252700; Email: add-tr.mitoteam@nhs.net
• Study Contact Backup: Name: Caterina Garone; Phone Number: +39 051 2094763; Email: caterina.garone@unibo.it

Study Locations

• United Kingdom
  • Cambridge, United Kingdom
    • Recruiting
    • Department of Clinical Neurosciences
    • Contact: Jelle van den Ameele; Phone Number: +44 (0) 1223252700; Email: add-tr.mitoteam@nhs.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The minimum required data for inclusion, and to allow verification of duplicate patients, will include year of birth, sex, and method of biochemical or genetic diagnosis of MNGIE as defined under the inclusion criteria. Patients may be living or deceased.

Description

Inclusion Criteria: All patients with a laboratory-confirmed TP deficiency:

• any age or stage of disease; living or deceased
• both previously published and unpublished patients
• symptomatic and asymptomatic patients

• TP deficiency defined by a and/or b and/or c:

  1. Homozygous or compound heterozygous pathogenic or likely pathogenic mutations in the TYMP gene; and/or
  2. Decreased TP enzyme activity <20% of normal; and/or
  3. Increased plasma dThd> 1 µmol/L, or increased plasma dUrd > 5 µmol/L.

Exclusion Criteria:

• There are no formal exclusion criteria for this retrospective observational study.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Survival time	At enrollment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demographics	Previously published in literature (if applicable refence DOI and patient number) Year and month of birth Current age Gender Ethnic Group Country of origin/birth Year at diagnosis (or, if not known, approximate age interval) Year at symptom onset Family history positive for MNGIE (if yes: to provide the number of family members with MNGIE, and study ID if data entered by same clinician)	At enrollment
Genetic diagnosis	Year at the time of genetic testing Type and date of genetic testing (WES, WGS, mtDNA fully sequenced, mtDNA panel, mtDNA tested by RFLP/Sanger, Panel sequencing, Single gene sequencing, Real-time PCR, Long-range PCR, Southern blot, Other) Mutation type Mutation at the cDNA level Mutation at the protein level (NM and NP)	At enrollment
Major clinical events	Age at the time of clinical events Bowel pseudo-obstructions Loss of ambulation Seizures Stroke-like episodes Surgeries Mechanical ventilation (hours of ventilation needed per day) Dependency on parental nutrition (type of parental feeding, amount of daily calories provided) Other	At enrollment
Collection of relevant medical history	Human Phenotype Ontology terms of medical history and clinical features (retrospective)	At enrollment
Collection of relevant technical investigations	Outcome of technical investigation (retrospective): ENG/NCS, EMG, EEG, Heart ultrasounds, Abdominal ultrasounds, Gastroscopy, Colonoscopy, Bowel Manometry, Laboratory sample analysis, Brain-Spine MRI, Other MRI, Other investigations	At enrollment
Collection of relevant tissue histology data		At enrollment
Newcastle Mitochondrial Disease Scale (Adult or Pediatric)		At enrollment
modified Rankin Scale		At enrollment
Talley Bowel Disease Questionnaire		At enrollment
Charcot-Marie-Tooth Neuropathy Score		At enrollment
Mini-mental state examination		At enrollment
Montreal Cognitive Assessment		At enrollment
Karnofsky Performance Scale		At enrollment
Short Form Survey (SF-36 or SF-12)		At enrollment
6-minute walk test		At enrollment
Timed water swallow		At enrollment
Clinical Global Impression Scale		At enrollment
Collection of relevant previous MNGIE-specific treatments	Age at the time of starting treatment: HSCT, LT, EE-TP, Hemodialysis, Peritoneal dialysis, Infertility treatments, Other treatments	At enrollment
Patient Global Impression Scale		At enrollment
Plasma nucleoside levels		At enrollment

Collaborators and Investigators

• Sponsor: University of Cambridge
• Collaborators: University of Bologna
• Investigators: Principal Investigator: Jelle van den Ameele, University of Cambridge; Principal Investigator: Caterina Garone, University of Bologna

Study record dates

Study Major Dates

• Study Start (Actual): March 17, 2026
• Primary Completion (Estimated): July 31, 2027
• Study Completion (Estimated): July 31, 2027

Study Registration Dates

• First Submitted: May 15, 2026
• First Submitted That Met QC Criteria: May 29, 2026
• First Posted (Actual): June 4, 2026

Study Record Updates

• Last Update Posted (Actual): June 4, 2026
• Last Update Submitted That Met QC Criteria: May 29, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Natural History Study; Retrospective data collection
• Other Study ID Numbers: HBREC.2025.15

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The University of Cambridge will maintain the confidentiality of all clinical participant data and will not disclose information by which participants may be identified to any third party; other staff that analyse the information will not be able to identify participants, and only anonymous study data, without any personal information will be published at the end of the study.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No